$PROF

Profound Medical presented data at the 15th Interventional MRI Symposium showing TULSA's real-world performance and clinical benefits. Mayo Clinic studies reported high continence and erection preservation rates, sustained PSA decline, and shorter catheter days. The CAPTAIN trial showed TULSA's superiority in preserving erectile function and continence compared to robotic prostatectomy. Technical validation confirmed TULSA's feasibility on Siemens 0.55T Free.Max.

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound

Profound Medical (PROF) and Telix Pharmaceuticals (TLX) partnered to educate physicians on combining PSMA-PET imaging and MRI-guided TULSA-PRO treatment for prostate cancer. The agreement focuses on U.S. and international markets, with plans for medical meetings, webinars, and clinical case studies. Profound is also developing software to integrate PSMA-PET and MRI imaging.

Raymond James reiterated a Strong Buy rating on Profound Medical (NASDAQ:PROF) with a $11.00 target, citing strong revenue growth and financial health. The company reported 61% revenue growth over the last year and expects $25.1M in 2026 revenue. Profound Medical also appointed Richard Fabian as President to scale sales and logistics.

Profound Medical (PROF) anticipates Q3 revenue of $9.8M-$10.0M, a 85%-89% YoY and 292%-300% QoQ increase, surpassing estimates by 45%-47%. Gross margin is expected to exceed 70%.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) reported preliminary Q3 2026 revenue of $9.8M-$10.0M, up 85%-89% YoY and 292%-300% QoQ. This exceeds analyst estimates by 45%-47%. Gross margin is expected to exceed 70%. The company will release full results on November 5, 2026.

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device c

The Dow fell 87.36 points, or 0.16%, to 53,372.42 Tuesday as oil rose above $90 amid Iran tension concerns. Home Depot reported fiscal Q2 sales of $47.86B vs ~$47.27B expected and adjusted EPS of $4.92 vs $4.73, reaffirming FY guidance. Memory chip stocks slid; other movers included Xos and Profusa.

Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) announced the launch of new real-time interventional MRI software, its latest Treatment Delivery Consol (TDC). The company says the most recent TDC software could help customers reach up to 6 TULSA Procedures per system per day, outlining a roadmap toward full “TULSA Days.”